Last reviewed · How we verify
Mesalamine Oral Product
At a glance
| Generic name | Mesalamine Oral Product |
|---|---|
| Also known as | 5-ASA |
| Sponsor | Dr. Falk Pharma GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Confirmatory Clinical Study in Active Ulcerative Colitis (PHASE2)
- Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis (PHASE2, PHASE3)
- Role of Roflumilast in Ulcerative Colitis (PHASE4)
- Mesalazine Oral Suspension in Active Eosinophilic Esophagitis (PHASE2)
- The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer (PHASE3)
- Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis (NA)
- Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy (PHASE3)
- Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesalamine Oral Product CI brief — competitive landscape report
- Mesalamine Oral Product updates RSS · CI watch RSS
- Dr. Falk Pharma GmbH portfolio CI